The aim of this study was to analyze patients by deep sequencing the human T cell lymphotropic virus type 1 (HTLV-1) long terminal repeat (LTR) region in order to determine if minor and/or major mutations in this promoter region might be associated with tropical spastic paraparesis (TSP)/human T cell lymphotropic virus type 1-associated myelopathy (HAM) outcome or proviral load or HTLV-1 expression. This study is a cross-sectional analyze of 29 HTLV-1-infected patients with TSP/HAM or asymptomatic carriers. Proviral DNA from those subjects was submitted to a nested PCR for the HTLV-1 LTR5¢ region. The HTLV-1 LTR5¢ purified products were submitted to deep sequencing using the Ion Torrent sequencing technology (Life Technologies, Carlsbad, CA). We found that samples with low proviral load showed more detected minor mutations than the samples with high proviral load. Mutations in 136 positions were found over the 520-bp analyzed fragment of HTLV-1 LTR5¢ with at least 1% frequency. Eleven mutations were present in the previously determined major transcription factor binding sites (TFBS) and in more than one patient, indicating that there might be a differential HTLV-1 expression comparing individuals or in comparing different cells from the same individual. Three mutations were statistically significant using the Fisher nonparametric test between the groups but were not present in previously determined TFBS (G126C/T, G306C, and C479T). Those mutations that were not present in previously determined TFBS were statistically significant in this study and were most frequent in patients with low proviral load or in asymptomatic carriers. Although those mutations were not present in previously determined TFBS, one of those mutations (G306C/A) was present in an Sp-1 binding site determined by in silico analysis, and its presence abrogated the site for Sp-1 binding and created a new possible ATF binding site.
H uman T cell lymphotropic virus type 1 (HTLV-1) is known to be the etiological agent of tropical spastic paraparesis/HTLV-1-associated myelopathy (TSP/HAM), 1, 2 adult T cell leukemia/lymphoma (ATL), 3 and other inflammatory diseases such as HTLV-1-associated uveitis (HAU) 4 and infective dermatitis associated with HTLV-1 (IDH). 5 The development of TSP/HAM in HTLV-1-infected individuals remains unknown, as few infected individuals develop this disease; it is probably related to environmental, host, and viral factors, such as proviral load, the methylation profile of proviral DNA, the integration site of HTLV-1 into the host genome, and viral mutations. [6] [7] [8] Recent studies have shown through Sanger sequencing and real-time PCR that mutations in the LTR region may increase HTLV-1 proviral load 9, 10 and could consequently affect TSP/HAM outcome. The HTLV-1 genome encodes the gag, pol, env, and pX genes, regulated by the LTR flanking region. The flanking regions are divided into three regions: U3, R, and U5, which contain signals to HTLV-1 expression control, such as the TxRE (Tax-responsive elements) region in U3 LTR5¢, 11 responsible for proviral genome transcription through the interaction with transcription factors such as CREB/ATF, the TATA box motif, and the poly(A) signal.
The aim of this study was to analyze patients by deep sequencing the HTLV-1 LTR region in order to determine whether minor and/or major mutations in this promoter region might be associated with TSP/HAM outcome, proviral load, or HTLV-1 expression.
To accomplish this a cross-sectional analysis of 29 HTLV-1-infected patients with TSP/HAM or asymptomatic carriers from the HTLV Center, Salvador, Brazil was carried out. Basic demographic and clinical information (age, sex, TSP/ HAM status, and proviral load) was obtained from the patient's clinical record. The patients were then classified according to their proviral load (high or low) and TSP/HAM status (present or absent). The Research Ethics Committee of the Oswaldo Cruz Foundation approved the project (Protocol Number 368/2011).
Patient nuclear DNA was extracted from peripheral blood mononuclear cell (PBMC) samples using a QIAGEN QIAamp DNA Blood kit following the manufacturer's protocol. DNA samples were submitted to nested PCR using the HTLV-1 long terminal repeat (LTR) 5¢ region primers as described previously. 12 The PCR products were purified using the PureLink PCR Purification kit. HTLV-1 sequencing was performed using the Taq FS Dye Terminator Cycle Sequencing kit (Applied Biosystems) on an automated 3130xl Genetic Analyzer (Applied Biosystems, Inc., Foster City, CA) using the identical nested PCR inner primers in order to analyze the major strains and create the consensus sequence for further deep sequencing analysis.
The HTLV-1 LTR5¢ purified products were submitted to deep sequencing using Ion Torrent sequencing technology (Life Technologies, Carlsbad, CA). At least 500 sequences with a minimum of 100 base pairs (bp) were produced for each specimen, which allowed characterization of the viral population at the 1% level. For Ion Torrent analysis the purified PCR products were submitted to enzymatic fragmentation following the manufacturer's conditions for the 100-ng-long amplicon input ( The generated sequence data were trimmed and then assembled with the consensus reference sequence using the highest sensitivity plus fine tuning followed by manual alignment of the mapped reads and single nucleotide polymorphisms (SNP) using the Geneious R6 Software application. 13 The SNP were manually filtered and statistically compared between groups using STATA. The HTLV-1 sequences were submitted to the LASP HTLV-1 Automated Subtyping Tool Version 1.0 14 for genotyping in order to exclude subtype-specific mutations. To analyze the transcription factor binding site (TFBS) modifications related to specific mutations we used the TFScan plugin of the Geneious software.
The selected patients were analyzed as to age and proviral load. The median age of asymptomatic carriers with a low proviral load was lower than the other groups but had no statistical significance (Table 1 ). The log proviral load was similar among the groups characterized as high proviral load (5.39 Asymptomatic X 5.27 TSP/HAM, p = 0.1551) but slightly different in the low proviral load group (2.99 Asymptomatic X 4.57 TSP/HAM, p = 0.0172) possibly due to the age difference.
The Ion Torrent sequencing showed a variable coverage depth between the samples ranging from 108.6x to 3740.5X (Table 1) . To avoid detecting subtype-specific mutations we submitted the sequences to the LASP HTLV-1 Automated Subtyping Tool Version 1.0 and all the sequences were classified as subtype a subgroup A. We described the mutations found on Ion Torrent as minor (if the mutation prevalence was lower than 50%) and major (if the mutation prevalence was higher or equal to 50%). We found that samples with a low proviral load showed more minor mutations than the samples with high proviral load.
We found mutations in 136 positions over the 520-bp analyzed fragment of HTLV-1 LTR5¢ with at least 1% frequency. Out of 136 mutations 52 were present in more than one patient, with 11 out of 52 present in the previously determined major TFBS ( Table 2 ). The other three mutations were statistically significant using the Fisher nonparametric test between the groups but were not present in previously determined TFBS (G126C/T, G306C, and C479T).
We performed an in silico analysis using TFScan of 11 mutations in the previously described TFBD plus those mutations with a statistical difference between groups and one deletion of 11 base pairs to determine possible modifications in the TFBS. We found that A153G, C167T, G199A, A207G, C215T, C219G/T, C268T, and G306C abrogated possible TFBS while T165C, C219G/T, T301A/C, and G306C/A created new possible TFBS ( Table 2) .
The Ion Torrent DNA sequencing was able to provide more information on HTLV-1 quasispecies than the Sanger sequencing, which lacks the sensitivity to show mutations at lower levels (20%). For HTLV-1 studies it is important to analyze quasispecies instead of viral populations because the virus is highly conserved with low evolutionary rates. [15] [16] [17] In addition, only around 1% of the infected cell will produce HTLV-1 proteins in a day, 18 which makes it important to analyze the mutations at 1% prevalence or even lower in studies, whereas the HTLV-1 mutations are being analyzed as disease outcome. The detection of mutations in approximately one in four analyzed sites by Ion Torrent sequencing with at least 1% frequency supports the use of this technique to search for minor mutations.
It was found that samples with low proviral load showed more detected minor variants than samples with high proviral load, which could be partly explained by the highest rate of clonal expansion of HTLV-1-infected cells. 7 Eleven mutations were present in the previously determined major TFBS and in more than one patient, indicating that there might be a differential HTLV-1 expression between individuals or in different cells from the same individual. Studies indicated that two mutations might be a marker for an increase in viral load 9, 10 and those mutations were usually found in the TFBS. We have searched one of those mutations to confirm the data previously described but we did not find any associations with proviral load; unfortunately all studies lacked sample size.
Three mutations that were not present in previously determined TFBS were statistically significant in this study and were most frequent in patients with low proviral load or in asymptomatic carriers. Despite the fact that those mutations were not present in previously determined TFBS, one of those mutations (G306C/A) was present in an Sp-1 binding site determined by in silico analysis, and its presence abrogated the site for Sp-1 binding and created a new possible ATF binding site.
The HTLV-1 promoter binding sites are not completely understood mainly because of the absence of chromatin immune precipitation analysis in the LTR promoter of HTLV-1-infecting T CD4
+ cells, and those mutations could decrease or increase the viral expression abrogating or creating TFBS. However, a further controlled study must be conducted in order to determine if there are transcription factors bound to those positions as well as the 11 positions in which mutations were found.
Sequence Data
The GenBank accession numbers of the new HTLV-1 LTR fragments included in the study are SRR2182833 to SRR2182854.
